Nitredon (Nitrazepam)

Nitrazepam binds to the benzodiazepine site on the GABA_A receptor complex, increasing the frequency of chloride channel opening when GABA binds. This amplifies the inhibitory effect of GABA, leading to neuronal hyperpolarisation, reduced excitability, and the clinical effects of sedation, anxiolysis, and anticonvulsant activity.

The appropriate dose of Nitredon is determined by the prescribing clinician based on the individual patient's condition, age, renal and hepatic function, and response to therapy. Dosage regimens are not standardized in public information and should follow the prescriber's instructions.

Safety data for nitrazepam in pregnancy and lactation are limited. Because benzodiazepines can cross the placenta and appear in breast milk, the drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Consultation with a healthcare professional is essential.

To request Nitredon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Nitredon (nitrazepam) shares the core mechanism of GABA_A modulation with other benzodiazepines but differs in its pharmacokinetic profile, potency, and duration of action. Compared with shorter‑acting agents like lorazepam, nitrazepam has a longer half‑life, which may be advantageous for insomnia but requires careful monitoring for accumulation.

Nitredon should be stored at room temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct light, and ensure they are out of reach of children.

Nitredon is taken orally, usually with a glass of water. The tablet should be swallowed whole and not crushed or chewed unless otherwise directed by a healthcare professional. Administration timing (e.g., before bedtime for insomnia) follows the prescriber's guidance.

Serious risks include respiratory depression, especially when combined with other central nervous system depressants, severe allergic reactions, and the potential for dependence or withdrawal seizures if the medication is stopped abruptly after prolonged use. Patients should be monitored closely for these events.

Nitredon is contraindicated in individuals with known hypersensitivity to nitrazepam or other benzodiazepines, patients with severe acute narrow‑angle glaucoma, and those with severe respiratory insufficiency. Caution is also advised for patients with a history of substance misuse or severe hepatic impairment.